Telix (NASDAQ: TLX) posts 24% Q1 revenue growth and advances late-stage pipeline

Rhea-AI Filing Summary

Telix Pharmaceuticals reports strong first-quarter momentum, with unaudited Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% from Q4 2025. Precision Medicine revenue reached US$186 million, rising 23% year-over-year as Illuccix and Gozellix dose volumes and market share increased.

The company reaffirmed its FY 2026 revenue guidance of US$950–970 million and R&D expenditure guidance of US$200–240 million, indicating continued heavy investment in its pipeline. TMS third-party revenue was US$44 million, up 29% year-over-year.

Telix highlighted multiple late-stage pipeline advances, including Part 1 of the global Phase 3 ProstACT trial for TLX591-Tx meeting safety and dosimetry objectives with no new safety signals, first-patient-in for pivotal trials in brain cancer and glioblastoma, and regulatory progress for imaging agents TLX101-Px (NDA resubmission in the U.S. and MAA filing in Europe) and TLX250-Px (preparing a BLA resubmission after successful FDA Type A meetings). Corporate updates include appointing David Gill as a new Non-Executive Director, with an expectation he will become Chair.

Positive

• Strong top-line growth: Q1 2026 unaudited group revenue reached US$230 million, up 24% year-over-year and 11% quarter-over-quarter, with Precision Medicine revenue growing 23% year-over-year.
• Reaffirmed robust guidance with heavy R&D investment: FY 2026 revenue guidance of US$950–970 million and R&D expenditure guidance of US$200–240 million were reaffirmed, supported by multiple late-stage clinical and regulatory milestones.

Negative

• None.

Insights

Biotech equity analyst

Telix combines strong Q1 revenue growth with visible late-stage pipeline progress.

Telix delivered unaudited Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% quarter-over-quarter. Precision Medicine revenue of US$186 million grew faster at 23% year-over-year, reflecting broader use of Illuccix and Gozellix across more countries.

The company reaffirmed FY 2026 revenue guidance of US$950–970 million and R&D spending of US$200–240 million, signaling confidence while maintaining substantial clinical investment. This is underpinned by the ProstACT Phase 3 Part 1 meeting safety objectives, FDA and European regulatory steps for TLX101-Px, and progress toward a BLA resubmission for Zircaix (TLX250-Px).

Future performance will hinge on execution of pivotal trials like ProstACT and LUTEON and on regulatory outcomes for TLX101-Px and TLX250-Px. Subsequent company reports and regulatory decisions will clarify how these late-stage assets convert into additional approved products and incremental revenue beyond Illuccix and Gozellix.

Key Figures

Q1 2026 group revenue: US$230 million Q1 2026 Precision Medicine revenue: US$186 million Q1 2026 TMS third-party revenue: US$44 million +3 more

6 metrics

Q1 2026 group revenue US$230 million Unaudited, up 24% year-over-year and 11% vs Q4 2025

Q1 2026 Precision Medicine revenue US$186 million Unaudited, up 23% year-over-year and 16% vs Q4 2025

Q1 2026 TMS third-party revenue US$44 million Up 29% year-over-year; flat vs Q4 2025

FY 2026 revenue guidance US$950–970 million Reaffirmed full-year revenue outlook

FY 2026 R&D expenditure guidance US$200–240 million Reaffirmed, subject to achieving global commercial milestones

Illuccix launch footprint 21 countries Commercially available, including 16 countries in Europe

Key Terms

Phase 3 trial, New Drug Application (NDA), Marketing Authorization Application (MAA), Biologics License Application (BLA), +2 more

6 terms

Phase 3 trial medical

"ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate"

A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.

New Drug Application (NDA) regulatory

"NDA resubmitted to the United States (U.S.) Food and Drug Administration (FDA)"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

Marketing Authorization Application (MAA) regulatory

"Marketing Authorization Application (MAA) filed in Europe"

A marketing authorization application (MAA) is a formal request submitted to a health regulator asking permission to sell a medicine or medical product in a market. Think of it like applying for a driver's license for a new drug: the regulator checks safety, quality and effectiveness before granting permission. For investors, the MAA stage matters because approval typically unlocks commercial sales and revenue, while rejection or delay creates major value and timing risk.

Biologics License Application (BLA) regulatory

"aligned on key outstanding issues for the Biologics License Application (BLA) resubmission"

A biologics license application (BLA) is a formal request to a government agency seeking approval to sell a biological medicine, such as vaccines or gene therapies, in the market. It is similar to a detailed report that proves the product is safe, effective, and manufactured properly. For investors, a BLA signifies a critical step toward commercial availability, often impacting a company's valuation and market prospects.

metastatic castration-resistant prostate cancer medical

"standard of care therapies for mCRPC10, including ARPIs11"

An advanced form of prostate cancer that has spread beyond the prostate to other parts of the body (metastatic) and no longer responds to treatments that lower male hormones designed to starve the tumor (castration-resistant). It matters to investors because it defines a high unmet medical need with limited treatment options, so clinical trial results, new drug approvals, or safety setbacks can sharply change the valuation and prospects of companies working in this area; think of it as a weed that has spread and become resistant to the usual weedkiller.

radiopharmaceuticals medical

"development and commercialization of therapeutic and diagnostic radiopharmaceuticals"

Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-

F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On April 7, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian

Securities Exchange titled “Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement,” a copy of

which is attached to this Form 6-K as Exhibit 99.1.

99.1 Press release – April 7, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: April 7, 2026	By:	/s/ Christian Krautkramer
		Name: Christian Krautkramer
		Title: Group General Counsel

1 Telix media release March 9, 2026. ClinicalTrials.gov ID: NCT06520345.

2 Telix ASX disclosure March 16, 2026.

3 Brand name subject to final regulatory approval.

4 Telix ASX disclosure February 18, 2026.

5 Branded as Illuccix in commercial jurisdictions outside of China.

6 Telix ASX disclosure January 20, 2026.

7 Primarily sales of Illuccix and Gozellix in our Precision Medicine business.

8 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS),

excludes Illuccix and Gozellix sales and TMS inter-segment revenue. Q1 2025 includes RLS revenue contribution since

acquisition close on January 28, 2025.

9 Prostate-specific membrane antigen.

Page 1

ASX ANNOUNCEMENT

Telix Pharmaceuticals Limited

ACN 616 620 369

55 Flemington Road

North Melbourne

Victoria, 3051

Australia

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline

Advancement

Melbourne (Australia) and Indianapolis, IN (U.S.) – April 7, 2026. Telix Pharmaceuticals Limited

(ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational

performance for the quarter ended March 31, 2026 (Q1 2026).

Q1 2026 Highlights

•Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.

•FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.

•Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-

quarter. Strong revenue growth in both Illuccix® and Gozellix® segments.

•ProstACT® Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1

lead-in met safety and dosimetry objectives, with no new safety signals observed1.

•TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted to the

United States (U.S.) Food and Drug Administration (FDA)2 for Pixclara®3. Marketing

Authorization Application (MAA) filed in Europe4 for Pixlumi®3.

•TLX591-Px5: NDA accepted in China by the National Medical Products Administration (NMPA)6.

Q1 2026 Revenue (Unaudited)

Revenue (US$M)	Q1 2026	Q1 2025	Variation	Q4 2025	Variation
Group revenue	230	186	24%	208	11%
Precision Medicine revenue7	186	151	23%	161	16%
TMS third-party revenue8	44	34	29%	44	—%

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Growth accelerated across

our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-

over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix,

contributing to market share gains underpinned by disciplined sales execution and pricing, and

high-quality service delivery despite extreme North American weather conditions, an advantage of

the pharmacy distribution model. With our two‑product PSMA9 imaging strategy, differentiated

clinical positioning and expanding commercial presence globally, we are seeing a solid foundation

for continued growth through 2026. Importantly, we are delivering on our strategic priorities to

advance our high-value clinical programs, demonstrated by the momentum in our therapeutics

pipeline this quarter."

10 Metastatic castration-resistant prostate cancer.

11 Androgen receptor pathway inhibitor.

12 ClinicalTrials.gov ID: NCT07197580.

13 Clear cell renal cell carcinoma.

14 ClinicalTrials.gov ID: NCT07100730.

15 ClinicalTrials.gov ID: NCT07197645.

16 ANZCTR.org.au ID: ACTRN12625000971437.

17 Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography.

18 Telix media release January 20, 2026.

Page 2

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product

candidates and disease areas. Q1 2026 highlights include:

•TLX591-Tx (lutetium (177Lu) rosopatamab tetraxetan): Part 1 of ProstACT Global, the Phase

3 trial of its lead prostate cancer therapy candidate, achieved its study objectives,

demonstrating an acceptable safety and tolerability profile with no new safety signals

observed1. No adverse drug-drug interactions were observed in TLX591-Tx combinations,

demonstrating the feasibility of integrating TLX591-Tx with current standard of care therapies

for mCRPC10, including ARPIs11 (enzalutamide or abiraterone) and docetaxel. Telix has

commenced engagement with the FDA to present data from Part 1 and ascertain eligibility for

U.S. patients to participate in Part 2 (randomized treatment expansion). Part 2 is open for

enrollment in Australia, New Zealand and Canada, with site activation underway in preparation

to open enrollment in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan,

where regulatory approvals have already been granted.

•TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan): Telix has opened its first clinical site

and is recruiting patients for Part 1 of LUTEON12, a pivotal trial of TLX250-Tx as a

monotherapy in advanced ccRCC13. Trial recruitment will initially focus ex-U.S.

•TLX101-Tx (131I-iodofalan): Telix has enrolled the first patient in IPAX-BrIGHT, an international,

multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma14. The trial is now

open for enrollment in Australia, Austria and the Netherlands and has received regulatory

approval to commence in Belgium.

•TLX090-Tx (153Sm-DOTMP): Telix continues to dose patients in SOLACE15, a Phase 1 study of

a drug candidate for treating pain in patients with osteoblastic bone metastases from prostate

and breast cancers. The study was expanded this quarter to include additional U.S. sites to

accelerate recruitment.

•TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA): TLX597-Tx is a "next generation" PSMA-

targeting prostate cancer therapy candidate being developed to facilitate patient access in

select geographies, where routine clinical availability to approved therapies is limited or not

available. Early clinical data suggests a favorable asset biodistribution with limited uptake in

healthy organs of concern (e.g., salivary glands, kidneys) relative to available 177Lu-PSMA

therapies. Interim data from OPTIMAL-PSMA16, an investigator-led, randomized, dose

intensification study of TLX597-Tx in mCRPC, will be presented at the International Prostate

Cancer Symposium in April 2026.

Precision Medicine Business Unit

PSMA imaging portfolio:

•Telix continues to expand its commercial footprint with Illuccix now launched in 21 countries

globally, which includes 16 countries in Europe. This growing international presence enhances

access to PSMA-PET/CT imaging17 while establishing a scalable commercial and operational

platform to support future product launches, including follow-on therapeutic products.

•Telix's broad proposed label for TLX591-Px (Illuccix) is under review by the NMPA Centre for

Drug Evaluation as part of the NDA submission18.

19 Telix ASX disclosure April 2, 2026. Appointment subject to grant of Australian Director Identification number.

20 Refer to Telix ASX disclosures February 20, 2026.

21 Telix ASX disclosure December 20, 2021.

22 Telix ASX disclosure March 21, 2025.

Page 3

TLX101-Px, (Floretyrosine F 18 or 18F-FET):

•Telix has resubmitted its NDA in the U.S. with the additional clinical data and analysis as

agreed with the FDA.

•Telix has submitted a MAA in Europe covering commercially significant markets, seeking to

expand patient access to advanced brain imaging.

Zircaix®3 (TLX250-Px, 89Zr-DFO-girentuximab):

•Based on two successful Type A meetings with the FDA, Telix believes it has aligned on key

outstanding issues for the Biologics License Application (BLA) resubmission, including

demonstration of drug product comparability between clinical trial material and scale-up

commercial production. The Company is now completing the agreed deliverables and

documentation required, targeting a H1 submission.

Corporate Updates

Telix has announced the appointment of David Gill as Non-Executive Director (NED), effective May

11, 2026, as part of its Board renewal process19. Mr. Gill is expected to be appointed as Chair in

due course, succeeding Dr. Mark Nelson who will remain on the Board as NED. The Board

believes Mr. Gill's appointment will enhance the Board’s capability, with extensive experience in

U.S. public company governance, financial oversight and senior leadership across commercial and

clinical-stage biopharmaceutical companies.

FY 2026 guidance

•Telix reaffirms FY 2026 revenue guidance of US$950 million to US$970 million20.

•Guidance reflects revenue from product sales in jurisdictions with a marketing

authorization, and a full year of revenue contribution from RLS.

•Telix reaffirms research and development (R&D) expenditure guidance of US$200 million to

US$240 million, subject to achieving ongoing global commercial milestones.

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of

therapeutic and diagnostic radiopharmaceuticals with the goal of addressing significant unmet

medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with

international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium

and Switzerland), and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and

the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the

FDA21, and in multiple markets globally. Gozellix (kit for the preparation of gallium-68 (68Ga)

gozetotide injection) has been approved by the FDA22. No other Telix product mentioned in this

announcement has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share

price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst

presentations, news releases, event details and other publications that may be of interest. You can

also follow Telix on LinkedIn, X and Facebook.

Page 4

Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor    Relations charlene.jaw@telixpharma.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on

behalf of the Board.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known

and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such,

investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular

result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have

been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and

development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions

regarding label claims; competitive developments affecting our products; the ability to successfully market new and

existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency

exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement,

access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s

ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information,

risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the

Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report

on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or

recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the

United States. The information and opinions contained in this announcement are subject to change without notification.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any

information or opinions contained in this announcement, including any forward-looking statements (as referred to below),

whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No

representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information

contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities

Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or

business developments. Forward-looking statements can generally be identified by the use of words such as “may”,

“expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these

words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties

and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially

from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking

statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market,

regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there

can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-

looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and

results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance

product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the

timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-

Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing

capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved;

Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates;

estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments

relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic

conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and

reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or

achievements may be materially different from those which may be expressed or implied by such statements, and the

differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Page 5

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix

Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience,

trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any

waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix

does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement

by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

FAQ

How did Telix Pharmaceuticals (TLX) perform financially in Q1 2026?

Telix reported unaudited Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% quarter-over-quarter. Precision Medicine revenue was US$186 million, reflecting strong growth from Illuccix and Gozellix across an expanding international footprint.

What revenue and R&D guidance did Telix (TLX) reaffirm for FY 2026?

Telix reaffirmed FY 2026 revenue guidance of US$950–970 million. It also maintained guidance for research and development expenditure of US$200–240 million, contingent on achieving ongoing global commercial milestones, underscoring continued investment in its therapeutics and imaging pipelines.

What are the key clinical milestones in Telix’s therapeutics pipeline for Q1 2026?

Part 1 of the ProstACT Global Phase 3 trial for TLX591-Tx met safety and dosimetry objectives with no new safety signals. Telix also opened pivotal trials LUTEON for TLX250-Tx, IPAX-BrIGHT for TLX101-Tx, and expanded the SOLACE study for TLX090-Tx dosing in more U.S. sites.

What regulatory progress did Telix (TLX) report for its imaging products?

Telix resubmitted a New Drug Application (NDA) for TLX101-Px in the U.S. and filed a Marketing Authorization Application (MAA) in Europe. For Zircaix (TLX250-Px), successful FDA Type A meetings paved the way for a Biologics License Application (BLA) resubmission targeted in the first half of 2026.

How is Telix’s Precision Medicine business performing and expanding geographically?

Precision Medicine revenue reached US$186 million in Q1 2026, up 16% quarter-over-quarter. Illuccix is now launched in 21 countries, including 16 in Europe, broadening access to PSMA-PET/CT imaging and establishing a platform to support future diagnostic and therapeutic launches.

What changes were announced to Telix’s Board of Directors in this period?

Telix announced the appointment of David Gill as a Non-Executive Director effective May 11, 2026, as part of Board renewal. He is expected to become Chair in due course, succeeding Dr. Mark Nelson, who will remain on the Board as a Non-Executive Director.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 164.3 KB